This medicine is also used to treat HIV. It contains two drugs that work together to fight the virus. It's usually taken as a pill, often once a day.
Every report comes from a Lived member, sent anonymously.
Have you tried Truvada (Emtricitabine/Tenofovir) for HIV Infection?
Truvada is a single tablet that combines two HIV medicines, emtricitabine and tenofovir disoproxil fumarate. It is available under the Truvada brand and as lower-cost generic versions with the same ingredients. It has two quite different jobs. The first is treating HIV, the virus that damages the immune system and, without treatment, can lead to AIDS. For this use Truvada is always combined with at least one other HIV medicine, because on its own it is not a complete treatment. It is approved for adults and for children who weigh at least 17 kg (about 37 pounds). The second is prevention, known as PrEP (pre-exposure prophylaxis). HIV-negative adults and adolescents who weigh at least 35 kg (about 77 pounds) and have a real chance of exposure take it to lower their risk of getting HIV through sex. US guidance from the Centers for Disease Control and Prevention (CDC) also recommends it for people who inject drugs. Other PrEP options now exist, including Descovy (a related pill with a different form of tenofovir that is not approved for people whose risk comes from receptive vaginal sex) and long-acting injections such as Apretude, given every two months, and Yeztugo, given every six months.
HIV cannot copy itself without an enzyme called reverse transcriptase, which turns the virus's genetic material into DNA that can take over a human cell. Emtricitabine and tenofovir both belong to the nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) family. Inside cells they are converted into look-alike building blocks that the enzyme mistakenly uses, which stops the viral DNA chain from being completed. In someone who already has HIV, this slows the virus's ability to multiply, which is why Truvada is paired with a drug that blocks HIV at a different step. In someone who is HIV-negative, enough of the drug needs to be built up in the body's tissues so that, if the virus enters, it is blocked before it can establish an infection. That is why steady daily dosing matters so much for PrEP.
The standard tablet (200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) is taken once a day by mouth, with or without food. Children treated for HIV who weigh 17 to 35 kg use lower-strength tablets matched to their weight. People with reduced kidney function may need doses spaced further apart for HIV treatment, and Truvada is not recommended for PrEP when kidney function is below a set level (an estimated creatinine clearance under 60 mL/min, a calculation from a blood test that reflects how well the kidneys filter). For PrEP, protection depends heavily on taking the pill consistently, and missed doses leave people at greater risk. The CDC estimates daily pills reach maximum protection after about 7 days for receptive anal sex and about 21 days for receptive vaginal sex and injection drug use. Some clinicians offer certain gay and bisexual men an off-label schedule called 2-1-1, timed around sex (two pills 2 to 24 hours before sex, then one pill 24 hours later and another 24 hours after that); it is not FDA-approved and is not suitable for everyone, including people with hepatitis B, so it should only be used with a clinician's guidance. Before starting, people are tested for HIV, hepatitis B and kidney function. For HIV treatment, skipping doses can let the virus become resistant, so steady daily use matters here too.
Many people taking Truvada for PrEP notice little or nothing. In prevention studies, headache, stomach pain and some weight loss were reported a bit more often than with placebo, usually early on. When Truvada is part of an HIV treatment regimen, diarrhea, nausea, tiredness, headache, dizziness, trouble sleeping, unusual dreams and rash are common, though some of these come from the other medicines taken with it. Tenofovir disoproxil fumarate can affect the kidneys and bones. Most changes in kidney function on PrEP are small and found on routine blood tests, but rarely the kidneys are injured more seriously. Bone density can drop slightly, more noticeably in teenagers and young adults. Persistent bone pain, muscle weakness or a fracture without a clear cause should be checked. A rare but serious reaction is a buildup of lactic acid in the blood, sometimes with severe liver problems. Unusual weakness with fast breathing, severe stomach pain with nausea and vomiting, or yellowing of the skin or eyes need contact with the care team right away. For people on PrEP, flu-like symptoms such as fever, sore throat, rash, night sweats or swollen glands can signal a recent HIV infection and should be reported promptly so testing can be done.
Truvada carries an FDA boxed warning, the agency's most prominent type, on two points. First, PrEP must only be started by someone confirmed to be HIV-negative, with repeat HIV testing at least every 3 months. If someone already has an undetected HIV infection, Truvada alone is not enough to control it, and the virus can become resistant to these drugs, limiting future treatment options. Second, in people who have hepatitis B, stopping Truvada can trigger a severe flare of liver inflammation, so anyone with hepatitis B should not stop without a plan from their clinician, who will monitor the liver for months afterward. Because the kidneys clear both drugs, combining Truvada with other medicines that strain the kidneys raises risk. High-dose or regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen (common pain relievers) is the everyday example to avoid; certain antiviral drugs for herpes or cytomegalovirus can also add to the load. Some HIV protease inhibitors and some hepatitis C medicines raise tenofovir levels, so the full medication list, including supplements and over-the-counter products, should be reviewed by the prescriber or pharmacist. Studies have not shown an increased risk of birth defects, and PrEP can be continued or started during pregnancy when HIV risk is present. For people treating HIV, infant feeding is a decision to make with the HIV care team: current US guidelines support breastfeeding for those whose virus stays suppressed on treatment, with extra monitoring for the baby, while the product label still advises against it. For PrEP, breastfeeding is an individual decision to discuss with the care team.
Starting PrEP involves a visit with HIV, hepatitis B and kidney tests, and often screening for other sexually transmitted infections. Prescriptions are usually written for up to 90 days, with an HIV test at each refill. Kidney checks continue at least yearly, and more often for people over 50 or those whose kidney function was already lower. Truvada does not protect against syphilis, gonorrhea, chlamydia or other sexually transmitted infections (STIs), so condoms and regular STI testing still matter. When taken consistently, the CDC estimates that PrEP lowers the risk of getting HIV from sex by about 99%, and from injection drug use by at least 74%. People can stop PrEP when their risk changes, ideally after talking with the clinician about how to stop and when to restart, particularly if they have hepatitis B. For HIV treatment, Truvada is one part of a long-term daily regimen. Regular viral load tests show whether the virus is being kept under control, and the care team may switch components over time based on kidney or bone health, side effects or convenience.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Truvada (Emtricitabine/Tenofovir), what you've noticed, or ask the community a question.